

Strategic co-localization of HCV testing with COVID-19 vaccination to enhance engagement among priority populations

Vanderhoff A^{1,2}, Biondi M^{1,2}, Logan R³, LeDrew E³, Enman S⁴, Van Uum R^{1,2}, You L^{1,2}, Smookler D^{1,2}, Wolfson-Stofko B^{1,2}, Domm B⁵, Johnston K⁵, Shah H, Janssen HLA^{1,2}, Capraru C^{1,2}, Venier E⁴, Feld JJ^{1,2}

¹Toronto Centre for Liver Disease, University Health Network, Toronto, ON; ²Viral Hepatitis Care Network (VIRCAN), Toronto, ON; ³Centre for Addiction and Mental Health, Toronto, ON; ⁴Addiction Medical Services, Toronto, ON; ⁵Ontario Addiction Treatment Centre, North Bay, ON

Land acknowledgement

We would like to acknowledge the traditional custodians of the land where we live and work including the Mississaugas of the Credit, the Anishnabeg, the Chippewa, the Haudenosaunee and the Wendat peoples and this land is now home to many diverse First Nations, Inuit and Métis peoples and express our gratitude to the community and Elders past and present.


Disclosure of interest

Personal disclosures - none

Grants

- AbbVie
- Gilead

80+
community
partners




48,000+
Canadians tested
for viral hepatitis
by our network
since 2016



Viral Hepatitis Care Network (VIRCAN)



COVID-19 interrupted HCV testing



- Significant reduction in testing volumes (▼ ~33%)
- Volumes do not return to pre-pandemic levels by the end of August 2020



Mandel et al. (2020) poster presented at Canadian Liver Meeting and the International Liver Conference

Pandemic → syndemic

- 50%+ ▲ overdoses
- Dislocation from services
- Toxic drug supply



Human wall around encampment
to protest displacement

Aims

- Evaluate the feasibility of hepatitis C testing combined with COVID-19 vaccination

Large mental
health hospital

**Outpatients and
members of the public**

Toronto, Ontario

OAT Clinic

**Patients and
household members**

North Bay, Ontario

Testing flow at vaccine clinics

HEPATITIS C
CAN CAUSE **LIVER CANCER**

1 OUT OF 3 people with Hepatitis C in Ontario don't know they have it until they have severe symptoms.

GET TESTED TODAY
FINGERSTICK TESTING
Fast • Free • Confidential


GIVE HEP C THE FINGER!

OVER 95% OF PEOPLE ARE CURED WITHIN 3 MONTHS.

AFTER YOUR VACCINE
In as little as 5 minutes, an antibody test can tell you if you've been exposed to hepatitis C.
If it's positive, more blood is needed to determine if you still have hepatitis C.

2 WEEKS FROM NOW
Results will tell you if you still have hepatitis C. If yes, treatment is available to cure it.
Sustained virologic response (SVR) can connect you to healthcare providers that can cure you of hepatitis C.

Logos: VIRCAN, TORONTO CENTRE FOR LIVER DISEASE, camh



HCV Ab POC testing workflow

Finger
prick



Anti-HCV POCT



Results in **5 minutes**
(VIRCAN 5-Minute Rule)



HCV RNA using
DBS card



Results in **1-2 weeks**



Same-day
phone call
with provider
or treatment
nurse

Smookler et al. (2020) Clin Gastro Hep


Demographics

	Hospital	OAT
Vaccine Doses	11923	150
Approached	4618 (39%)	150 (100%)
HCV Ab POCT	2317 (50%)	27 (18%)
Avg. Age (yrs)	42	37
Male (%)	46.2	66.6

- **79%** members of the public
- **12%** staff
- **9%** outpatients


89% had no knowledge of receiving a prior HCV test

OAT clinic: Diagnosis and linkage to care



- 7 Ab+ (26%)
- Re-engagement of known cases
- 2 tested for re-infection
- 1 invalid sample
- 2 pending treatment
- 1 LTFU


Recruitment at CAMH vaccine clinic



Reasons for refusal:

- “Not interested”
- “Overwhelmed/vaccination is all I can handle today”
- “I don’t like needles/fingerprick”
- “Tested elsewhere”
- “Tested here before”

CAMH: Diagnosis and linkage to care



- 31 Ab+ (1.3%)
- 3 Ab+ after 5 minutes
- 3 refused DBS
- Low reinfection rate
- 2 LTFU
- 1 pending treatment

CAMH: Antibody prevalence among groups

Gender	Tested <i>n</i> (%)	Ab+ <i>n</i> (%)
Men	1073 (46.3)	20 (1.9)
Women	1220 (52.7)	11 (0.8)
Trans/Intersex/ Genderfluid	24 (1.0)	0 (0.0)

Age years	Tested <i>n</i> (%)	Ab+ <i>n</i> (%)
< 35	959 (41.4)	9 (0.9)
35-45	448 (19.3)	6 (1.3)
46-76	859 (37.1)	16 (1.8)
77+	51 (2.2)	0 (0.0)

Group	Tested <i>n</i> (%)	Ab+ <i>n</i> (%)
Public & Staff	1696 (73.2)	17 (1.0)
Patient	192 (8.3)	5 (2.6)
Unknown	429 (18.5)	9 (18.4)

Challenges

- Outpatient recruitment was lower than expected
- Linkage to care still a challenge
- Safety in context of COVID
- Mixed response to incorporating it in other vaccine clinics

Conclusions

- Leverages resources put into the fight against COVID to address other public health challenges
- May allow us to overcome some of the dropoff of testing and linkage to care that has occurred due to the pandemic
- Can be done with a small footprint
- Enables reaching and re-engaging populations with a tenuous link to the healthcare system
- POCT with the 5-Minute Rule followed by DBS sample collection allows high throughput and ensures complete diagnosis